Table 1 Baseline characteristics of gynecological cancers (GC) patients receiving and refusing radiotherapy
Variables | All (n = 208,093) | Radiation (n = 206,867) | Refuse radiation (n = 1226) | P |
|---|---|---|---|---|
Age (years), n (%) | < 0.001 | |||
<40 | 21,454 (10.3%) | 21,387 (10.3%) | 67 (5.46%) | |
40–65 | 118,284 (56.8%) | 117,774 (56.9%) | 510 (41.6%) | |
>65 | 68,355 (32.8%) | 67,706 (32.7%) | 649 (52.9%) | |
Race, n (%) | 0.969 | |||
Black | 19,843 (9.54%) | 19,726 (9.54%) | 117 (9.54%) | |
Others | 18,419 (8.85%) | 18,308 (8.85%) | 111 (9.05%) | |
White | 169,831 (81.6%) | 168,833 (81.6%) | 998 (81.4%) | |
Marital status at diagnosis, n (%) | < 0.001 | |||
Divorced | 22,284 (10.7%) | 22,136 (10.7%) | 148 (12.1%) | |
Married | 109,802 (52.8%) | 109,310 (52.8%) | 492 (40.1%) | |
Separated | 2905 (1.40%) | 2885 (1.39%) | 20 (1.63%) | |
Single | 41,561 (20.0%) | 41,319 (20.0%) | 242 (19.7%) | |
Widowed | 31,541 (15.2%) | 31,217 (15.1%) | 324 (26.4%) | |
Residence, n (%) | 0.303 | |||
Rural | 154,493 (74.2%) | 153,599 (74.3%) | 894 (72.9%) | |
Urban | 53,600 (25.8%) | 53,268 (25.7%) | 332 (27.1%) | |
Income ($), n (%) | < 0.001 | |||
<36,580 | 67,432 (32.4%) | 66,981 (32.4%) | 451 (36.8%) | |
36,580–42,810 | 69,269 (33.3%) | 68,710 (33.2%) | 559 (45.6%) | |
>42,810 | 71,392 (34.3%) | 71,176 (34.4%) | 216 (17.6%) | |
Unemployed, n (%) | < 0.001 | |||
<52.4% | 66,969 (32.2%) | 66,684 (32.2%) | 285 (23.2%) | |
52.4-71.4% | 69,825 (33.6%) | 69,378 (33.5%) | 447 (36.5%) | |
>71.4% | 71,299 (34.3%) | 70,805 (34.2%) | 494 (40.3%) | |
Education (less than high school), n (%) | 0.009 | |||
<18.75% | 67,875 (32.6%) | 67,522 (32.6%) | 353 (28.8%) | |
18.75-28.20% | 70,021 (33.6%) | 69,601 (33.6%) | 420 (34.3%) | |
>28.20% | 70,197 (33.7%) | 69,744 (33.7%) | 453 (36.9%) | |
Language isolation, n (%) | 0.368 | |||
<1.87% | 62,776 (30.2%) | 62,390 (30.2%) | 386 (31.5%) | |
1.87-2.82% | 74,999 (36.0%) | 74,551 (36.0%) | 448 (36.5%) | |
>2.82% | 70,318 (33.8%) | 69,926 (33.8%) | 392 (32.0%) | |
Foreign born, n (%) | 0.025 | |||
<5.04% | 67,895 (32.6%) | 67,535 (32.6%) | 360 (29.4%) | |
5.04-15.66% | 68,648 (33.0%) | 68,207 (33.0%) | 441 (36.0%) | |
>15.66% | 71,550 (34.4%) | 71,125 (34.4%) | 425 (34.7%) | |
Surgery, n (%) | < 0.001 | |||
Not Performed | 18,500 (8.89%) | 18,397 (8.89%) | 103 (8.40%) | |
Recommended but not performed | 3546 (1.70%) | 3430 (1.66%) | 116 (9.46%) | |
Yes | 186,047 (89.4%) | 185,040 (89.4%) | 1007 (82.1%) | |
Grade, n (%) | < 0.001 | |||
Well differentiated (grade I) | 63,653 (30.6%) | 63,409 (30.7%) | 244 (19.9%) | |
Moderately differentiated (grade II) | 62,448 (30.0%) | 62,053 (30.0%) | 395 (32.2%) | |
Poorly differentiated (grade III) | 62,432 (30.0%) | 61,982 (30.0%) | 450 (36.7%) | |
Undifferentiated/anaplastic (grade IV) | 19,560 (9.40%) | 19,423 (9.39%) | 137 (11.2%) | |
Primary site, n (%) | < 0.001 | |||
Cervical cancer | 35,033 (16.8%) | 34,801 (16.8%) | 232 (18.9%) | |
Endometrial cancer | 119,348 (57.4%) | 118,450 (57.3%) | 898 (73.2%) | |
Ovarian cancer | 47,360 (22.8%) | 47,327 (22.9%) | 33 (2.69%) | |
Vulvar cancer | 6352 (3.05%) | 6289 (3.04%) | 63 (5.14%) | |
Chemotherapy, n (%) | < 0.001 | |||
No/Unknown | 136,824 (65.8%) | 135,727 (65.6%) | 1097 (89.5%) | |
Yes | 71,269 (34.2%) | 71,140 (34.4%) | 129 (10.5%) | |
AJCC stage, n (%) | 0.127 | |||
I/II | 182,462 (87.7%) | 181,405 (87.7%) | 1057 (86.2%) | |
III/IV | 25,631 (12.3%) | 25,462 (12.3%) | 169 (13.8%) | |
Overall survival, n (%) | < 0.001 | |||
Survival | 128,204 (61.6%) | 127,593 (61.7%) | 611 (49.8%) | |
Death | 79,889 (38.4%) | 79,274 (38.3%) | 615 (50.2%) |